CAS: 3416-26-0; Lidoflazine

该化合物是化学化合物,主要因其药理特性而得到承认,属于被称为苯并呋喃的化合物类别,其特点是含有硫磺和氮原子的三环结构.利多弗拉津的特性使其作为血管除尘器有用,并已被调查其在治疗心血管病方面的潜在应用.该化合物已知与各种...

结构式图片

合成工艺路线路线简述

    📜(+)-Isolysergic Acid Amide 反应生成 利多氟嗪
    参考文献:Magone,Karacsony,E.;Balogh,T.;Lang,T.;Uskert,A.;Dancsi,L.;Kiss,J.;+
    标题:Magone,Karacsony,E.;Balogh,T.;Lang,T.;Uskert,A.;Dancsi,L.;Kiss,J.;+

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2008300418-A1
    优先权日:2004-11-08
    标 题:Synthesis of Cardiolipin Analogues and Uses Thereof
    发明人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    权利人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    摘要:The invention provides novel synthetic methodologies for preparing cardiolipin, migrated caridiolipin (1,2-positional isomer of cardiolipin) and their analogues having varying fatty acids and/or alkyl chains with varying length and degrees of saturation/unsaturation. The method comprises (a) reacting an optically pure 1,2-O-dialkyl-sn-glycerol or 1,2-O-dialkyl-sn-glycerol with one or more phosphoramidite reagent(s), wherein a phosphite triester is produced; (b) coupling the product of (a) with glycerol, wherein a protected cardiolipin is produced; and (c) deprotecting the protected cardiolipin, such that cardiolipin is prepared. The cardiolipins and analogues thereof, prepared by the present methods, can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or can be used in diagnostic and/or analytical assays.

    专利号:US-2008214827-A1
    优先权日:2004-02-03
    标 题:Synthesis of Cyanoimino-Benzoimidazoles
    发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
    权利人:EURO CELTIQUE SA
    摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

    专利号:US-2006078560-A1
    优先权日:2003-06-23
    标 题 :Method of inducing apoptosis and inhibiting cardiolipin synthesis
    发明人:JAMIL HARIS; AHMAD MOGHIS U; AHMAD IMRAN
    权利人:NEOPHARM INC
    摘要:The present invention provides a method for inducing apoptosis within a cell by exposing the cell to an inhibitor of cardiolipin synthesis under conditions sufficient to induce apoptosis within the cell. The method can be used to investigate or treat disorders such as cancer, obesity, and cardiovascular disorders. The invention also provides a pharmaceutical composition including an inhibitor of cardiolipin synthesis and a liposomal carrier.

    专利号:US-2008286351-A1
    优先权日:2004-06-29
    标 题:Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
    发明人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    权利人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
    摘要:The invention provides synthetic methods for PEGylated cardiolipins with varying linkers. The methods can be employed to prepare PEGylated cardiolipin with different fatty acid and/or alkyl chain length with or without unsaturation. The PEGylated cardiolipin, prepared by the present methods, can be incorporated into liposomes that can also include active agents such as hydrophilic or hydrophobic drugs for the treatment of human and animal diseases. In addition, the PEGylated cardiolipin can be incorporated into liposomes that include compounds for therapeutic and diagnostic imaging. The use of such liposomes with PEGylated cardiolipin prolongs the period of liposomal circulation without disrupting the lipid bilayer.

    专利号:US-2007203079-A1
    优先权日:2005-11-21
    标题:Methods of using small molecule compounds for neuroprotection
    发明人:CALDWELL GUY A; CALDWELL KIM A; CAO SONGSONG
    权利人:CALDWELL GUY A; CALDWELL KIM A; CAO SONGSONG
    摘要:Methods are provided for preventing neurodegeneration and neuronal loss by administering compositions comprising small molecule compounds with the effect of preventing neurodegeneration and neuronal loss. In one aspect of the invention, the methods and compositions are also useful for treating neurodegenerative diseases. Small molecule compounds provide an important treatment option because of their stability, ease of use in both manufacture and formulation, ease of administration, and patient compliance. The small molecule compound compositions of the present invention may include topoisomerase II inhibitors, bacterial transpeptidase inhibitors, calcium channel antagonists, cyclooxygenase inhibitors, folic acid synthesis inhibitors, or sodium channel blockers and functional analogues thereof that have an effect on neurodegeneration. The compositions of the present invention may be administered prophylactically before the onset of clinical symptoms or after clinical symptoms of a neurodegenerative disease have manifested.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: St-Onge M, Dubé PA, Gosselin S, Guimont C, Godwin J, Archambault PM, Chauny JM, Frenette AJ, Darveau M, Le Sage N, Poitras J, Provencher J, Juurlink DN, Blais R. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila). 2014 Nov;52(9):926-44. doi: 10.3109/15563650.2014.965827. Epub 2014 Oct 6. Review.
    2: Shively M, Norton L, Mendez K. Neurologic outcomes after cardiac resuscitation. J Cardiovasc Nurs. 1996 Jul;10(4):93-6. Review. Review. Review. Review. French. Review. Review. Review. Review. Review. Review.
    12: Van Nueten JM, Janssens WJ, Vanhoutte PM. Serotonin and vascular reactivity. Pharmacol Res Commun. 1985 Jul;17(7):585-608. Review. Review. Review. Italian. Review. Review. Review. Review. Italian. Review. Review. French.

    合成参考文献


    参考文献:10.1007/bf00261211
    摘要:Markov AK, Smith RO, Oglethorpe NC, Lehan PH, Hellems HK. The use of coronary vasodilators in myocardial imaging with 43K. European Journal of Nuclear Medicine and Molecular Imaging. 1980 Feb;5(1):75–84. doi: 10.1007/bf00261211.
    参考文献:10.1007/s002280050153
    摘要:Andersen K, Dellborg M, Swedberg K. Nucleoside transport inhibition by draflazine in unstable coronary disease. European Journal of Clinical Pharmacology. 1996 Sep 02;51(1):7–13. doi: 10.1007/s002280050153.
    参考文献:10.1007/s001340050912
    摘要:Plöchl W, Krenn CG, Pokorny H, Pezawas L, Pezawas T, Steltzer H. The use of the antioxidant tirilazad mesylate in human liver transplantation: is there a therapeutic benefit Intensive Care Med. 1999 Jun;25(6):616–9. doi: 10.1007/s001340050912.
    参考文献:10.1016/1010-7940(92)90176-x
    摘要:Noyez L, Knape JT, Arnold BJ, Vermeulen PM, van der Werf T, Gimbrère J, Lacquet LK, Flameng W. Evaluation of myocardial protection by combination of lidoflazine pretreatment and St. Thomas' Hospital cardioplegia in aorto-coronary bypass grafting. Eur J Cardiothorac Surg. 1992;6(7):377–81. doi: 10.1016/1010-7940(92)90176-x.
    参考文献:10.1016/0011-2240(92)90031-v
    摘要:Jacobsson J, Odlind B, Tufveson G, Wahlberg J. Improvement of renal preservation by adding lidoflazine to University of Wisconsin solution. An experimental study in the rat. Cryobiology. 1992 Jun;29(3):305–9. doi: 10.1016/0011-2240(92)90031-v.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知